Cambridge Healthtech Institute’s 15th Annual
Driving Clinical Success in Antibody-Drug Conjugates
Designing the Magic Bullet
May 15-16, 2025
As of 2023, the FDA has approved 15 ADC drugs in clinical oncology. More ADCs are expected to receive FDA approval in 2024-2025, a testament to the ongoing excitement and groundbreaking developments in ADCs for cancer treatment. The Driving Clinical Success in Antibody-Drug Conjugates conference will highlight novel payload strategies, including tumor-selective options, degraders, and antisense/siRNA approaches, as well as the potential of multi-payload ADCs. We will also explore advanced engineering techniques aimed at enhancing tumor selectivity, internalization, and penetration, alongside innovations in Fc and linker design. Drawing from clinical experiences, this conference will address strategies to overcome toxicity and drug resistance. By bringing together leading researchers, clinicians, and industry experts, we aim to drive the next wave of ADC innovations and expand their therapeutic reach.
- Novel/Alternate Payloads and Mechanisms-of-Actions
- Beyond TOPO1 inhibitors
- Tumor-selective payloads
- Beyond toxins as payloads—degraders/PROTACs, antisense/siRNA
- Dual/multiple payloads in one ADC
- ADC Engineering and Design—Increasing the Therapeutic Window
- Engineering antibody for more tumor selectivity
- Engineering ADCs for better internalization and penetration
- Engineering the Fc
- Engineering the linkers
- Overcoming Toxicity and Drug Resistance—Lessons from the Clinic
- Beyond Oncology
- Target Diversification
The deadline for priority consideration is October 11, 2024.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: